Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Why Is Twist Bioscience Corporation (TWST) Stock Down -8.25% Today?

Why Is Twist Bioscience Corporation (TWST) Stock Down -8.25% Today?

Key Takeaways

  • TWST shares fell 8.25% to $102.41, near the session low, from a prior close of $111.62 — a decline of $9.21.
  • No fresh company announcement accompanied the drop; the move extends the post-earnings de-rating that began after fiscal fourth-quarter results on Nov. 12.
  • Fiscal 2027 revenue guidance of $550 million to $560 million implies AI drug discovery growth slowing to roughly 69% from 175% in fiscal 2026.
  • A steady stream of price-target cuts — UBS to $120, Barclays to $130, Jefferies to $125 — keeps pressure on a premium valuation.
  • Insider Form 144 filings and a Nov. 5 short-seller report questioning the valuation remain unresolved overhangs.
  • The stock is the weakest performer among its small-cap biotech and life-science tools peers today, trading more than 50% below its October high near $220.
  • News Significance Score: 28/100 — Moderate analyst and guidance-driven news, but the move was only about 1.6x the stock's typical daily swing.
  • Traders are watching the Dec. 1 Evercore fireside chat, the fiscal first-quarter report expected in early February, and whether AI drug discovery revenue runs above a $25 million quarterly pace. More detail is available on Tickeron's Price Targets, Earnings, and Forecast pages.
  • For a broader view of how quantitative strategies are positioned right now, explore Trending AI Robots.

Opening Summary

Twist Bioscience Corporation (TWST) makes synthetic DNA on silicon chips, selling synthetic genes, next-generation sequencing target-enrichment tools, oligo pools and antibody discovery services to drug developers and academic labs. The stock traded at $102.41 in morning action, down 8.25% from the previous session's close of $111.62, with the direction unambiguously negative. Shares had indicated a milder decline near $106 in pre-market trading before opening at $102.50 and staying pinned close to the low. No new press release, filing or macro release explained the slide; the decline is a continuation of the selling that followed the company's fiscal 2026 fourth-quarter report and the valuation debate it triggered.

Post-Earnings De-Rating Resumes

The Nov. 12 report itself was solid. Revenue rose 28% to $126.6 million, ahead of the $123.6 million consensus, and adjusted EBITDA turned positive at $2.2 million — a milestone management had promised. Full-year revenue reached a record $459.4 million, up 22%.

The problem was the outlook. Fiscal 2027 guidance of $550 million to $560 million implies total growth of roughly 20% to 22%, with about $100 million from AI-enabled drug discovery — around 69% growth versus 175% in fiscal 2026. For a stock that had nearly quadrupled during 2026, that deceleration was the trigger. Shares have not recovered since, and the pattern of failed rebounds — including a 3.9% bounce on Nov. 18 and a reversal on Nov. 19 that closed 4.07% lower — left the stock vulnerable to further liquidation once support gave way.

Analyst Price-Target Cuts and Valuation Skepticism

Sell-side estimates have been recalibrated sharply, and the cuts kept accumulating this week. Barclays trimmed its target to $130 from $215, UBS to $120 from $190, Jefferies to $125 from $150, Baird to $135 from $187, Guggenheim to $150 from $212, Canaccord to $150 from $205 and TD Cowen to $137 from $190. The common thread is a lower multiple applied to forward revenue and concern that execution must now prove the AI franchise is additive rather than a substitute for slower core growth.

Even after the decline, the equity remains valued at roughly $7 billion, or close to 12 times the midpoint of next year's revenue guidance net of about $582 million in cash — a multiple that assumes sustained high growth. That math is what keeps sellers active on rallies.

Insider Selling and Short-Seller Scrutiny

Disclosure flow has added to the pressure. Recent Form 144 and Form 4 filings showed chief executive Emily Leproust selling shares, including roughly 19,000 shares reported in mid-November. While programmatic sales are routine, they land poorly during a valuation reset. A Nov. 5 report from short-seller The Bear Cave arguing the share price had outrun fundamentals produced an 11% to 12% one-day drop and never fully left the narrative.

Market Context and Trading Activity

Activity has been heavy. The stock averages about 2.5 million shares a day, and recent down sessions have traded at or above that pace, including 2.5 million on Nov. 12 and 2.25 million on Nov. 19 — evidence of broad distribution rather than a single large print. Today's action opened with a gap lower and little intraday recovery, a signature of persistent supply.

TWST is the clear laggard within its small-cap biotech and life-science tools cohort, which is trading with a much smaller spread. Technically, the shares are now well below their 30-day moving average near $160 and beneath the 100-day average, with only the rising 200-day line — around $90 at the start of the month — providing a distant floor. The stock sits roughly 53% below its 52-week high of $219.71 but remains up more than 250% year to date.

News Significance Score

The score runs from 0, meaning no meaningful news and a normal price move, to 100, meaning transformative news and an extreme, rare move. This event earns 28 out of 100.

The verified news was moderate: no new disclosure today, but a genuine fundamental reset in fiscal 2027 guidance plus a cluster of analyst target cuts at a premium valuation. The price move was only about 1.6 times the stock's typical daily swing of roughly 5.3% over the past three months, and moves of this size or larger occurred 13 times in the last 69 sessions. Modest news and an unremarkable move combine into a low score.

What Comes Next for TWST

The next hard catalyst is the fiscal first-quarter report, expected in early February, where investors will test whether AI drug discovery revenue can sustain a quarterly pace above $25 million. Management is also scheduled to appear at the Evercore health conference on Dec. 1, offering another opportunity to clarify the capacity expansion and $150 million, two-year capital plan funded from existing cash.

Consensus remains constructive — a Buy rating with an average target near $129 — but dispersion is wide. Risks include continued multiple compression, further estimate revisions, insider supply, and the possibility that core sequencing and synthetic biology demand grows slower than the guide assumes. Sentiment toward high-multiple small-cap growth names will likely matter as much as fundamentals in the interim.

Trending AI Robots

Tickeron's Trending AI Robots page curates the strongest performing automated strategies under current market conditions, drawn from a library of hundreds of AI trading bots covering thousands of tickers. Bots differ by strategy logic, timeframe, performance metrics and the symbols they trade, so the featured list changes as market conditions shift. For traders who want quantitative signals alongside their own research, reviewing the current leaders is a practical next step.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TWST

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


TWST in downward trend: price dove below 50-day moving average on October 30, 2026

TWST moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend. In 28 of 29 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TWST as a result. In 62 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for TWST turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 37 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

The 10-day moving average for TWST crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

TWST broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TWST entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 63 cases where TWST's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

Following a +10.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 235 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.967) is normal, around the industry mean (3.596). P/E Ratio (-54.166) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TWST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -16%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of proprietary semiconductor-based synthetic DNA manufacturing process

Industry Biotechnology

Industry
Biotechnology
Address
681 Gateway Boulevard
Phone
+1 800 719-0671
Employees
979
Web
https://www.twistbioscience.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.